This is of particular interest as studies show that mid-chain HETE serum concentrations are elevated in patients with advanced prostate cancer (Rodríguez-Blanco et al., 2014), indicating that perhaps CYP1B1 and mid-chain HETEs contribute to prostate cancer progression. Here, CYP1B1 is linked to prostate carcinoma.